Status:
COMPLETED
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Lead Sponsor:
Bayer
Conditions:
Liver Neoplasms
Eligibility:
All Genders
Brief Summary
Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
Eligibility Criteria
Inclusion
- Patients with confirmed diagnosis of unresectable HCC
- Physician-initiated decision to treat with regorafenib (prior to study enrollment)
Exclusion
- Participation in an investigational program with interventions outside of routine clinical practice
- Past treatment with regorafenib
Key Trial Info
Start Date :
September 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 21 2022
Estimated Enrollment :
1010 Patients enrolled
Trial Details
Trial ID
NCT03289273
Start Date
September 13 2017
End Date
June 21 2022
Last Update
June 13 2023
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
2
St. Joseph´s Hospital and Medical Center
Phoenix, Arizona, United States, 85013
3
University of Florida Health
Gainesville, Florida, United States, 32610
4
University of Louisville - Clinical Trials Unit
Louisville, Kentucky, United States, 40202